ArticleNature communications2024
Incidence and transmission of respiratory syncytial virus in urban and rural South Africa, 2017-2018.
Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- Respiratory Syncytial Virus Transmission in Closed Community Settings That Include Children: A Systematic Review and Meta-Analysis.Influenza and other respiratory viruses · 2026Pooled it
- Mucosal IgA to pre-fusion F protein predicts protection from RSV infection in a high burden setting.Nature communications · 2026Article
- Burden of Hospitalized Respiratory Syncytial Virus in Children in Sweden: A Population-based Case-cohort Study (2006-2023).The Pediatric infectious disease journal · 2026Article
- Viral variant but not host factors associate with SARS-CoV-2 viral kinetics.Communications medicine · 2026Article
- The influence of age-dependent susceptibility on RSV transmission dynamics and immunisation population-level impact.BMC medicine · 2026Article
- Kinetics of antibodies and risk of respiratory syncytial virus infection: a longitudinal cohort in Taizhou City, eastern China.BMC medicine · 2026Article
- Household Transmission and Genomic Diversity of Respiratory Syncytial Virus in the United States, 2022-2023.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- New insight into the epidemiological trends of respiratory syncytial virus infection and the underlying anti-respiratory syncytial virus mechanisms of andrographolide: integrating Global Burden of Disease database, network pharmacological analysis, andMicrobiology spectrum · 2026Article
- Molecular Surveillance RevealsVaccines · 2025Article
- Prophylactic monoclonal antibodies against respiratory syncytial virus in early life: An in-depth review of mechanisms of action, failure factors, and future perspectives.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2025Review
- The top 100 most cited articles on pediatric respiratory syncytial virus pneumonia over the last 30 years: a bibliometric analysis.Tropical medicine and health · 2025Article
- The relative contribution of close-proximity contacts, shared classroom exposure and indoor air quality to respiratory virus transmission in schools.Nature communications · 2025Article
- Age-specific antibody profiles of respiratory syncytial virus after COVID-19 pandemic: a sero-epidemiological survey in Taizhou City, Eastern China.BMC infectious diseases · 2025Article
- Characterizing social behavior relevant for infectious disease transmission in four low- and middle-income countries, 2021-2023.Nature communications · 2025Article
- Sociodemographic Factors, Intent-Uptake Disparities, and Nirsevimab Availability in Infant RSV Immunoprophylaxis.Pediatric reports · 2025Article
- Feasibility and Acceptability of Respiratory Syncytial Virus Vaccination in Mothers for Infant Protection at Edward Francis Small Teaching Hospital, the Gambia.Journal of epidemiology and global health · 2025Article
- Respiratory Syncytial Virus Epidemiology and Clinical Burden in High-Risk and ≥ 50-Year-Old Adults in Low- to Middle-Income Countries: An Artificial-Intelligence-Enabled Systematic Literature Review.Infectious diseases and therapy · 2025Article
- Correlates of risk of respiratory syncytial virus disease: a prospective cohort study.Nature communications · 2025Article
- Relating In Vivo Respiratory Syncytial Virus Infection Kinetics to Host Infectiousness in Different Age Groups.The Journal of infectious diseases · 2025Article
- Determinants of respiratory syncytial virus and human metapneumovirus transmission.Clinical microbiology reviews · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 6 institutions in 2 countries.
Funding
Abstract
Data on respiratory syncytial virus (RSV) incidence and household transmission are limited. To describe RSV incidence and transmission, we conducted a prospective cohort study in rural and urban communities in South Africa over two seasons during 2017-2018. Nasopharyngeal swabs were collected twice-weekly for 10 months annually and tested for RSV using PCR. We tested 81,430 samples from 1,116 participants in 225 households (follow-up 90%). 32% (359/1116) of individuals had ≥1 RSV infection; 10% (37/359) had repeat infection during the same season, 33% (132/396) of infections were symptomatic, and 2% (9/396) sought medical care. Incidence was 47.2 infections/100 person-years and highest in children <5 years (78.3). Symptoms were commonest in individuals aged <12 and ≥65 years. Individuals 1-12 years accounted for 55% (134/242) of index cases. Household cumulative infection risk was 11%. On multivariable analysis, index cases with ≥2 symptoms and shedding duration >10 days were more likely to transmit; household contacts aged 1-4 years vs. ≥65 years were more likely to acquire infection. Within two South African communities, RSV attack rate was high, and most infections asymptomatic. Young children were more likely to introduce RSV into the home, and to be infected. Future studies should examine whether vaccines targeting children aged <12 years could reduce community transmission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.